Tejas Patil, MD, surveys forthcoming presentations on advances in the treatment of advanced non-small cell lung cancer at American Society of Clinical Oncology (ASCO) 2024. In particular, Dr Patil looks forward to new data on first-line approaches for KRAS G12C mutations, especially concerning high-risk somatic alteration signatures like KEAP1 or STK11.
In addition, he looks forward to insights into antibody-drug conjugates for second-line therapy, with a focus on TROP-2 antibody-drug conjugates. Last, he anticipates updates on the development of novel tyrosine kinase inhibitors targeting EGFR, ALK, and RET rearrangements, expecting significant strides in personalized treatment options for patients with advanced NSCLC.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Tejas Patil. ASCO 2024: Anticipating New Data in Advanced NSCLC - Medscape - May 23, 2024.
Comments